Share Price, page-8828

Here the best thing that Pilcher can do is to demonstrate (and he is doing so) that 2591 can be exploited in a series of pathologies, even those of enormous dimensions. Once this has been done, it must be sold to the best offer that guarantees simultaneous multi-studies on unsatisfied needs, all of this also for an ethical issue for patients, Neuren has already done too much for its capabilities, wanting to move forward alone would postpone any developments to the detriment of the patients, this is what I think, so I hope that in the not too distant future Neuren no longer exists because that's right.